南京医科大学学报（自然科学版）2017，Vol.37Issue(8)：1019-1022,4.DOI:10.7655/NYDXBNS20170820
肿瘤异常蛋白及血清肿瘤标记物评估乳腺癌新辅助化疗效果的意义
Tumor abnormal protein (TAP) and serum tumor markers in assessing the effect of neoadjuvant chemotherapy of breast cancer
摘要
Abstract
Objective:This article aimed to study the value of tumor abnormal protein (TAP) and serum tumor markers (including CEA,CA125 and CA 15-3) in the evolution of efficacy of neoadjuvant chemotherapy (NCT) in locally advanced breast cancer (LABC).Methods:In this retrospective study,68 LABC patients received NCT were enrolled.They were classified into pathologic complete response (pCR),partial response (PR),stable disease (SD) and progression of disease (PD) according to the therapy efficacy (some patients received targeted therapy at the same time).We set group pCR and PR as reaction group,SD and PD as no reaction group.All patients received tests for TAP,CEA,CA125 and CA15-3 before and after NCT.We compared results of these tests and their changes to finds out whether there exists statistical difference between reaction group and no reaction group.Results:In accordance with the comparison among test figures before and after NCT,there were statistical significance in TAP after NCT between two groups (P＜0.05).And comparison among the numerical changes showed that there were statistical significance in TAP and CA15-3 before and after NCT.Conclusion:TAP and CA15-3 may play a role in the evolution of NCT efficacy in LABC patients.关键词
乳腺癌/新辅助化疗/肿瘤异常蛋白/肿瘤标记物Key words
breast cancer/neoadjuvant chemotherapy/TAP/tumor markers分类
医药卫生引用本文复制引用
陈锐,王珏,印梓楠,张岭,谢菲,赵佳,查小明..肿瘤异常蛋白及血清肿瘤标记物评估乳腺癌新辅助化疗效果的意义[J].南京医科大学学报（自然科学版）,2017,37(8):1019-1022,4.基金项目
江苏省六大人才高峰(2013-WSW-026) （2013-WSW-026）
